The Algebra of Organic Synthesis combines the aims, philosophies, and efforts involved in organic synthesis, reaction optimization, and green chemistry with techniques for determining quantitatively just how "green" synthesis plans are. It provides the first complete quantitative description of synthesis strategy analysis in the context of green ch
Furnishing the latest interdisciplinary information on the most important and frequently the only investigational system available for discovery programs that address the effects of small molecules on newly discovered enzyme and receptor targets emanating from molecular biology, this timely resource facilitates the transition from classical to high throughput screening (HTS) systems and provides a solid foundation for the implementation and development of HTS in bio-based industries and associated academic environments.
An acknowledged expert on the history of modern pharmacology and drug therapy, John Parascandola here brings together 19 of his most important papers on these subjects. The book is divided into three topical sections. In the first group of articles, devoted to pharmacological theory, Dr. Parascandola sheds new light on our understanding of the history of such key pharmacological concepts as receptor theory, structure-activity relationships, and the role of stereochemistry in physiological action. The second section focuses on the discipline of pharmacology and offers insights into the pivotal role played by John J. Abel in the shaping of the field, the development of pharmacology in schools of pharmacy and in the Federal Government, and the national pharmacological society's membership ban on pharmacologists working in industry. The final section on drug therapy discusses various drugs from antibiotics to sulfones, and their use in the treatment of diseases such as leprosy and syphilis.
A searing exposé of the misuses and misrepresentations of science from the time of Galileo continuing through to the present day, this new edition includes updates on the asbestos industry, the chemicals industry, the sugar industry, the agriculture industry (the abuse of antibiotics), and the automobile industry (lead in gasoline). The final chapter has been expanded to include the full-blooded assault on science mounted by the Trump administration.
Tracing the international and Australian history of both licit and illicit drug use, this investigation combines the topic of drug use with analyses of political power, the rise of the market, and social issues. It examines the way in which drug consumption is regulated in the era of global free trade by first looking at the start of the opium-growing industry and the racist origins of drug laws. Providing a social history of drug use through the lens of international politics, market forces, medicine, and race, this discussion also considers the paradox of contemporary, white Australian identity and an Australia as a nation of people whose per capita drug consumption often equals and surpasses that of most other nations.
Expanded and updated, the new edition of the bestselling Clinical Protocols in Obstetrics and Gynecology is the definitive quick-reference for use in office practice and hospital settings. With information drawn from ACOG technical bulletins, OB/GYN publications, articles, textbooks, computer sources, and the author's vast personal experience, outl
Managing Innovation: New Technology, New Products, and New Services in a Global Economy, 2nd Edition is devoted to providing a better understanding and better management of all of the causes and consequences of change that have technological implications in and around our global organizations. This text is a unique, original contribution and represents a significant alternative to the collection of chapters written by others. The second edition has new cases with a few classics from the first edition that have been retained in response to reader feedback. The key subjects that are included have been significantly updated and treated in greater depth. The number of chapters has been reduced from 12 to 10 so it is easy to adapt to almost any course or training on the subject in any discipline or to any audience. This exceptionally informative book provides a broad perspective on how technological change can be effectively managed in modern organizations. The text explains the conceptual frameworks supported by new and original case studies for start-up companies like Askmen.com, the complex challenges of managing international technology-based companies like NexPress (a joint venture of Kodak and Heidelberg) in the digital printing industry, and corporate sustainability using innovative new product technologies illustrated by the case of Evinrude’s launch of the E-tec® outboard motor. John E. Ettlie's three decades in the field of innovation as an instructor and researcher bring an exceptional perspective to this subject. His text is unique in its discussion of how technology has transformed the service sector. Few books on technology make the distinction between new offerings in manufacturing and the service sector which is emphasized in this text.
First published in 1984, this book examines corporate crime in the pharmaceutical industry. Based on extensive research, including interviews with 131 senior executives of pharmaceutical companies in the United States, the United Kingdom, Australia, Mexico and Guatemala, the book is a major study of white-collar crime. Written in the 1980s, it covers topics such as international bribery and corruption, fraud in the testing of drugs and criminal negligence in the unsafe manufacturing of drugs. The author considers the implications of his findings for a range of strategies to control corporate crime, nationally and internationally.
This book discusses the connectivity between major chemicals, showing how a chemical is made along with why and some of the business considerations. The book helps smooth a student’s transition to industry and assists current professionals who need to understand the larger picture of industrial chemistry principles and practices. The book: Addresses a wide scope of content, emphasizing the business and polymer / pharmaceutical / agricultural aspects of industrial chemistry Covers patenting, experimental design, and systematic optimization of experiments Written by an author with extensive industrial experience but who is now a university professor, making him uniquely positioned to present this material Has problems at the end of chapters and a separate solution manual available for adopting professors Puts chemical industry topics in context and ties together many of the principles chemistry majors learn across more specific courses
John Sutton sets out a unified theory that encompasses two major approaches to studying market, while generating a series of novel predictions as to how markets evolve. Traditionally, the field of industrial organization has relied on two unrelated theories—the cross-section theory and the growth-of-firms theory—to explain cross-industry differences in concentration and within-industry skewness. The two approaches are based on very different mathematical structures and few researchers have attempted to relate them to each other. In this book, John Sutton unifies the two approaches through a theory that rests on three simple principles. The first two, a "survivor principle" that says that firms will not pursue loss-making strategies, and an "arbitrage principle" that says that if a profitable opportunity is available, some firm will take it, suffice to define a set of possible outcomes. The third, the "symmetry principle," says that the strategy used by a new entrant into any submarket depends neither on the entrants identity nor on its history in other submarkets. This allows researchers to bring together the roles of strategic interactions and of independence effects. The result is that the considerations motivating the cross-section tradition and those motivating the growth-of-firms tradition both drop out within a single game-theoretic model. This book follows Sutton's Sunk Costs and Market Structure, published by MIT Press in 1991.
This large print, extensively updated edition covers the many advances that have been made in understanding how the diet works, how it should be used, and its future role as a treatment for children with epilepsy. Included is a new section on how the Atkins diet and a modified ketogenic diet can be used as alternative nutritional therapies. This new edition also has an expanded section with recipes and sample meals developed by professional chefs.
The flying public, airlines, and governments will all agree on one date that changed commercial flying: that was September 11, 2001. The first edition of Aviation Law: Cases, Laws and Related Sources, described early consequences of that event, particularly compensation of victims and early tightening of aviation security. Subsequently laws and regulations affecting all aspects of aviation changed so rapidly that it became difficult to set a cut-off date for the second edition. The rapid flow of events made an update urgent. Several gaps in the materials of the first edition became evident as the book was used. The authors filled those gaps, pruned old materials and added much new material describing not only the later developments, but also evolving economics and flight technology. The objective of the case book is to offer a basic handbook for air law practitioners providing them with a starting point for almost any subject they may encounter. For example, a lawyer specializing in liability law will quickly be able to find basic materials on the International Civil Aviation Organization (ICAO), air carrier licensing, FAA certification, and labor law. The book continues to present aviation law from the American point of view. Thus the book will be valuable for foreign air lawyers who are guiding foreign airlines in service to the very important North American pool of air traffic. The book also explains the international scene to American air lawyers so that they may guide their clients who provide foreign service. New chapters on liability for cargo damage and for ground damages have been added and new materials on the legal rights of lessors, successors, actual carriers and code-shares. A chapter on environmental regulation of aviation noise and emissions is also new. All the main subjects listed in the first edition are significantly updated. The three authors are veteran transportation lawyers and continue their activities in this field.
High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include: Fiscal consequences of curing hepatitis C mRNA vaccines and the race for a cure Why the government does not deserve a piece of Biopharma’s profits Paying for drugs whose ultimate value is unknown The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
I am unaware of any textbook which provides such comprehensive coverage of the field and doubt that this work will be surpassed in the foreseeable future, if ever!' From the foreword by Robert C. Moellering, Jr., M.D, Shields Warren-Mallinckrodt Professor of Medical Research, Harvard Medical School, USA Kucers' The Use of Antibiotics is the leading major reference work in this vast and rapidly developing field. More than doubled in length compared to the fifth edition, the sixth edition comprises 3000 pages over 2-volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into 4 sections: antibiotics, anti-fungal drugs, anti-parasitic drugs and anti-viral drugs, and is highly structured for ease of reference.Within each section, each chapter is structured to cover susceptibility, formulations and dosing (adult and paediatric), pharmacokinetics and pharmacodynamics, toxicity and drug distribution, detailed discussion regarding clinical uses, a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with a vast number of contributors spanning Europe, Africa, Asia, Australia, South America, the US and Canada, the sixth edition adopts a truly global approach. It will remain invaluable for anyone using antimicrobial agents in their clinical practice and provides in a systematic and concise manner all the information required when treating infections requiring antimicrobial therapy. Kucers' The Use of Antibiotics is available free to purchasers of the books as an electronic version on line or on your desktop: It provides access to the entire 2-volume print material It is fully searchable, so you can find the relevant information you need quickly Live references are linked to PubMed referring you to the latest journal material Customise the contents - you can highlight sections and make notes Comments can be shared with colleagues/tutors for discussion, teaching and learning The text can also be reflowed for ease of reading Text and illustrations copied will be automatically referenced to Kucers' The Use of Antibiotics
This book answers the questions about the process and costs of pharmaceutical R & D in a compelling narrative focused on the discovery and development of important new medicines. It gives an insider's account of the pharmaceutical industry drug discovery process, the very real costs of misperceptions about the industry, the high stakes--both economic and scientific--of developing drugs, the triumphs that come when new compounds reach the market and save lives, and the despair that follows when new compounds fail. In the book, John LaMattina, former president of Pfizer Global Research and Development, weaves themes critical to a vital drug discovery environment in the context. This is a story that Dr. LaMattina is uniquely qualified to tell.
One of the leading IP law journals in the world presents it second special symposium issue to go ebook (the 2010 issue, available as well, centered on the "green" movement). This edition of John Marshall RIPL is the new 2011 Special Issue, with seven cutting-edge articles from recognized lawyers and scholars of IP law and biotech/health sciences. Each spring, RIPL produces a symposium law review issue. In this important contribution, RIPL presents very current articles on emerging biotech research and industries, and their promotion through IP law, including patents and trademarks. Topics include encouraging biotech innovation through patent protection, the risks and advantages of DIY scientists, plain packaging of tobacco, research funding of small projects, the materiality doctrine for inequitable conduct, patenting genetic materials, EU law on patent infringement, and health care reform's effect on drug research. The volume is also useful and accessible to non-lawyers interested in these issues and the way they are affected by legal and policy decisions.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.